After a CEO share sale, 528,621 shares remain with Mineralys Therapeutics (MLYS) chief.
Mineralys Therapeutics (MLYS) CEO Jon Congleton sold 75,000 shares of common stock on September 30, 2026, for a weighted-average price of $25.4622 per share, totaling approximately $1.91 million. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Congleton directly holds 528,621 shares of the company.
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
Mineralys Therapeutics will present new data from its Launch-HTN trial of lorundrostat at the American Society of Nephrology Kidney Week 2026. The data will highlight blood pressure and albuminuria reduction in chronic kidney disease stages 1-3. Lorundrostat is an investigational aldosterone synthase inhibitor aimed at treating uncontrolled hypertension and related comorbidities driven by dysregulated aldosterone.
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics announced that five abstracts detailing data on its investigational drug, lorundrostat, will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026. The presentations will cover findings from the Explore-OSA and Launch-HTN trials, focusing on lorundrostat's efficacy and safety in treating hypertension, obstructive sleep apnea, and its cardiorenal benefits. The company aims to highlight the drug's potential as a highly selective aldosterone synthase inhibitor for dysregulated aldosterone conditions.
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
Mineralys Therapeutics will present five abstracts related to its investigational drug, lorundrostat, at the American Heart Association Hypertension Scientific Sessions 2026. The presentations will cover data from the Explore-OSA and Launch-HTN trials, focusing on lorundrostat's efficacy and safety in treating hypertension and obstructive sleep apnea. The company aims to highlight the potential of lorundrostat as a highly selective aldosterone synthase inhibitor for dysregulated aldosterone conditions.
Form 144 Mineralys Therapeutics For: 1 October By Investing.com
This article from Investing.com reports on a Form 144 filing by Mineralys Therapeutics for October 1. The brief piece includes the stock symbol MLYS, which saw a -5.61% change. It is primarily a notification of the filing rather than an in-depth analysis.
A 75,000-share sale is proposed by a Mineralys (MLYS) officer and director.
Jon Congleton, an officer and director of Mineralys Therapeutics, Inc. (MLYS), has proposed selling 75,000 common shares valued at approximately $1.91 million. This notice also disclosed two prior sales by Congleton: 75,000 shares on June 30, 2026, for $1.96 million and 10,700 shares on July 13, 2026, for $291,441. The proposed sale is made pursuant to Rule 144, with 88,406,885 shares outstanding as of September 30, 2026.
Two new hires at Mineralys receive options on 46,430 shares and stock awards tied to 34,823 shares.
Mineralys Therapeutics (Nasdaq: MLYS) granted equity inducement awards to two new non-executive employees on September 28, 2026, comprising 46,430 stock option shares and 34,823 restricted stock units. These awards, part of the 2025 Employment Inducement Incentive Award Plan, vest over four years subject to continued service and were granted as an inducement for employment under Nasdaq Listing Rule 5635(c)(4). The grants introduce potential shareholder dilution through stock options and restricted stock units.
Mineralys to Present Long-Term Lorundrostat Data in November
Mineralys Therapeutics will present new long-term efficacy and safety data for its investigational hypertension treatment, lorundrostat, at the American Heart Association Scientific Sessions 2026 in November. The data comes from the ongoing Transform-HTN open-label extension trial, evaluating the drug's long-term effects in patients with hypertension. Lorundrostat, an oral aldosterone synthase inhibitor, has shown promise in reducing blood pressure and plasma aldosterone concentrations, addressing a significant need in hypertension treatment where current therapies often fall short.
Mineralys Sets Investor Forum Appearance as Lorundrostat Advances
Mineralys Therapeutics (NASDAQ: MLYS) will participate in the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026. The company's management will host a fireside chat to discuss the advancement of lorundrostat, their lead product candidate for hypertension and related conditions. A live webcast of the event will be available on the Investor Relations section of the Mineralys Therapeutics website.
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com
This article reports on a Form 4 filing for Mineralys Therapeutics Inc., specifically for September 24th. The filing indicates insider trading activity for the company. The stock symbol for Mineralys Therapeutics Inc. is MLYS, and it experienced a -3.29% change.
A fund sold Mineralys (MLYS) shares and still holds more than 7.8 million.
Catalys Pacific Fund, LP, associated with Mineralys Therapeutics, Inc. director Brian Taylor Slingsby, sold 104,320 common shares of MLYS on September 22, 2026, at a weighted-average price of $28.8085 per share. Following this transaction, the fund still holds a significant 7,805,718 shares. Slingsby disclaims beneficial ownership of these shares except for his pecuniary interest.
Mineralys Therapeutics (NasdaqGS:MLYS) Stock Price
Mineralys Therapeutics (MLYS) is highlighted as potentially undervalued, with analyst fair value estimates ranging from $31.65 to $56, suggesting significant upside. The company is advancing lorundrostat, an aldosterone synthase inhibitor, for hypertension and cardiorenal conditions, with promising late-stage clinical trial data and an upcoming late-breaking presentation at the American Heart Association Scientific Sessions. Despite recent net losses, the company is well-funded with $661M in cash, positioning it for a strong commercial launch of lorundrostat following an anticipated FDA approval.
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com
This article from Investing.com is a regulatory filing announcement, specifically a Form 4 for Mineralys Therapeutics Inc. dated September 24. It indicates a required disclosure of changes in ownership of company stock by insiders. The article provides the title of the filing and its publication date without further details.
Mineralys Therapeutics director sells $3 million in shares By Investing.com
A director at Mineralys Therapeutics, Brian Taylor Slingsby, indirectly sold 104,320 shares of common stock for approximately $3 million on September 22, 2026. This transaction was executed by Catalys Pacific Fund, LP, at a weighted-average price of $28.8085 per share. Despite the stock's 27% year-to-date decline and a recent wider-than-expected loss reported by the company, four analysts have revised their earnings estimates upwards for the upcoming period, and InvestingPro suggests the stock is currently undervalued.
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Mineralys Therapeutics will present new long-term efficacy and safety data from its Transform-HTN open-label extension trial of lorundrostat at the American Heart Association Scientific Sessions 2026. Lorundrostat is an investigational aldosterone synthase inhibitor aimed at treating uncontrolled or resistant hypertension and related conditions. The data will highlight its potential as an effective treatment for a significant portion of hypertensive patients who do not achieve blood pressure goals with current medications.
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Mineralys Therapeutics (Nasdaq: MLYS) announced its participation in the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026. Management will host a fireside chat at 12:00 PM ET, which will be accessible via webcast on the company's investor relations page. Mineralys Therapeutics is a biopharmaceutical company focused on developing treatments for hypertension and related conditions.
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com
This article reports on a Form 4 filing for Mineralys Therapeutics Inc. dated September 24, 2026. Form 4 filings are used to disclose transactions by company insiders and are important for investors to track changes in insider holdings. The brief piece includes the company's stock symbol MLYS, which saw a -2.75% change.
Long-term results for a blood pressure drug will be presented at an American Heart Association meeting
Mineralys Therapeutics (MLYS) announced that long-term efficacy and safety data for its aldosterone synthase inhibitor, lorundrostat, will be presented at the American Heart Association Scientific Sessions 2026 on November 8, 2026. The data comes from the ongoing Transform-HTN open-label extension trial, which studies the drug in patients with uncontrolled hypertension. The presentation will cover the drug's potential benefits for patients with hypertension and related comorbidities.
Mineralys Therapeutics CCO Eric Warren sells $209k in stock
Mineralys Therapeutics' Chief Commercial Officer, Eric Warren, sold 7,438 shares of company stock worth $209,135 on September 21, 2026, through a pre-arranged trading plan after exercising stock options. Despite the insider sale, analysts have recently raised earnings expectations for the company. Mineralys Therapeutics also reported a larger-than-expected loss in Q2 2026 due to increased spending on its blood pressure drug, lorundrostat.
Mineralys Therapeutics’ Transform-HTN Open-Label Extension
Mineralys Therapeutics announced that long-term efficacy and safety data from its Transform-HTN open-label extension trial of lorundrostat will be presented at the American Heart Association Scientific Sessions 2026. Lorundrostat is an investigational aldosterone synthase inhibitor being developed for uncontrolled or resistant hypertension and related comorbidities. The company highlights that lorundrostat has demonstrated robust reductions in systolic blood pressure and a favorable safety profile in previous clinical trials.
Mineralys Therapeutics CCO Eric Warren sells $209k in stock By Investing.com
Mineralys Therapeutics' Chief Commercial Officer, Eric Warren, sold 7,438 shares of common stock for $209,135 on September 21, 2026, under a Rule 10b5-1 plan. This transaction followed his acquisition of the same number of shares through stock options. Despite the insider sale, analysts have revised earnings upwards, though the company recently reported a larger-than-expected loss in Q2 2026 due to increased spending on its blood pressure drug.
Form 144 Mineralys Therapeutics For: 23 September By Investing.com
This article announces the filing of Form 144 for Mineralys Therapeutics, specifically noting it is for September 23. It includes the stock symbol MLYS, which saw a 3.85% increase. The piece is brief, primarily serving as an announcement of the filing from Investing.com.
Form 144 Mineralys Therapeutics For: 23 September By Investing.com
This article announces the filing of Form 144 for Mineralys Therapeutics on September 23. It's a very brief news item from Investing.com, typical of regulatory filings updates, and includes the stock symbol MLYS.
Form 4 Mineralys Therapeutics Inc For: 22 September
The article announces the filing of Form 4 by Mineralys Therapeutics Inc. for September 22. It mentions the company's stock symbol MLYS and its positive performance, being up 3.85%. The content otherwise largely consists of market data, news headlines, and navigational elements from the Investing.com platform.
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com
This article announces the filing of a Form 4 for Mineralys Therapeutics Inc., specifically for transactions that occurred on September 22. It is a brief news update published by Investing.com, indicating insider trading activity for the company MLYS.
Fund may sell Mineralys (NASDAQ: MLYS) shares; filing shows the size
A shareholder of Mineralys Therapeutics (MLYS), Catalys Pacific Fund, has filed a Rule 144 notice indicating a potential sale of 104,320 common shares. These shares, valued at approximately $3.0 million, were acquired in a private transaction in 2022. The filing notes that 88,406,885 shares are outstanding as of September 22, 2026, and Morgan Stanley Smith Barney LLC is listed as the broker for the potential sale on NASDAQ.
Mineralys Therapeutics (MLYS) officer lines up new stock option sale
An officer of Mineralys Therapeutics, Eric Warren, has filed a Rule 144 notice to sell 7,438 shares of common stock on September 21, 2026, via a broker-assisted cashless option exercise, valued at approximately $209,135.39. This proposed sale follows several prior stock sales by Warren in recent months, with the company's outstanding shares listed at 88,406,885. The filing provides details on the acquisition of these securities and information on previous sales by the officer within the last three months.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics announced inducement stock option and restricted stock unit awards to a new non-executive employee under its 2025 Employment Inducement Incentive Award Plan. The awards, covering 14,880 shares for options and 11,160 shares for RSUs, will vest over four years, subject to continued service, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Mineralys Therapeutics is a biopharmaceutical company focused on developing treatments for hypertension and aldosterone-related conditions.
Mineralys Therapeutics (MLYS) CCO sells 7,438 shares in pre-set plan
Mineralys Therapeutics' Chief Commercial Officer, Warren Eric, exercised stock options for 7,438 shares at $13.24 per share and subsequently sold them at a weighted-average price of $28.1172 per share on September 21, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 stock selling plan adopted on March 27, 2026. Following these transactions, Eric directly holds 230,563 stock options and 38,400 shares of common stock.
Mineralys Therapeutics director Karydas sells $85,740 in stock
Daphne Karydas, a director at Mineralys Therapeutics (NASDAQ:MLYS), recently sold $85,740 worth of common stock after exercising options. These transactions, executed under a Rule 10b5-1 trading plan, involved selling 3,000 shares at $28.58 each following an option exercise at $12.02 per share. Despite the stock being down 23% year-to-date, analysts predict significant upside, with price targets up to $56.
Mineralys at Wells Fargo conference: lorundrostat launch takes shape By Investing.com
Mineralys Therapeutics outlined its commercialization strategy for its blood-pressure drug, lorundrostat, at the Wells Fargo 21st Annual Healthcare Conference. The company is preparing for a December 22, 2025 FDA decision and aims for parity access in a market with existing competition. Mineralys highlighted strong clinical data, robust financial backing, and a targeted sales approach to address the significant unmet need in uncontrolled and resistant hypertension.
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com
Eric Warren, Chief Commercial Officer at Mineralys Therapeutics, sold 7,437 shares of the company's common stock for $193,188, following the exercise of stock options. These transactions occurred under a Rule 10b5-1 selling plan. The company recently reported a wider-than-expected loss for Q2 2026, driven by investments in its blood pressure drug, lorundrostat.
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan
Mineralys Therapeutics, Inc. (MLYS) Chief Commercial Officer Eric Warren sold 7,437 shares of common stock at a weighted-average price of $25.9767 per share on August 21, 2026, following the exercise of stock options. These transactions were conducted under a Rule 10b5-1 stock selling plan adopted on March 27, 2026. After the sale, Warren holds 238,001 stock options and 38,400 common shares directly.
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal
Mineralys Therapeutics, Inc. (MLYS) officer Eric Warren has filed a Rule 144 notice to sell 7,437 shares of common stock on August 21, 2026, stemming from the exercise of employee stock options. This planned sale follows two previous sales by Warren within the last three months, totaling 104,124 shares for $2,696,321.98 on June 26, 2026, and 7,438 shares for $199,884.80 on July 21, 2026. The upcoming transaction has an aggregate market value of $193,188.40.
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management
Mineralys Therapeutics, Inc. has appointed Jessica Wagner Keliher, SPHR, as Vice President, Talent Management. Keliher brings over two decades of human resources leadership experience from the biotech and life sciences sectors, including previous roles at Cartesian Therapeutics, Novavax, and Kite Pharma. Her new role will focus on shaping the people and culture strategy as Mineralys Therapeutics prepares for the commercialization of its lead hypertension treatment, Lorundrostat.
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56
This article provides a snapshot of analyst ratings for Mineralys Therapeutics (MLYS.US), with forecasts ranging from $40 to $56. It offers insights into the company's market position and future financial expectations from various financial institutions.
Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS
The Timothy G. Youngquist 2020 Irrevocable Trust has acquired a new position in Mineralys Therapeutics, Inc. (MLYS) worth approximately $2.72 million, representing 0.12% of the company. Despite this institutional interest, the company recently reported a significant earnings miss, and while analysts have a consensus "Hold" rating with a $49.33 price target, insider selling has also occurred. Mineralys Therapeutics, headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on developing therapies for hypertension and chronic kidney diseases.
TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS
TimesSquare Capital Management LLC has invested $6.36 million in Mineralys Therapeutics, Inc. by acquiring 235,858 shares, representing a 0.29% stake in the company. Despite significant institutional ownership (84.46%), insiders have recently sold shares, totaling $5.61 million. Mineralys Therapeutics reported a wider-than-expected quarterly loss of $2.85 per share, and analysts currently maintain a "Hold" rating with an average price target of $49.33.
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run
Mineralys Therapeutics, Inc. insider David Rodman has filed to sell 417 shares of common stock, valued at $10,616.82, through Merrill Lynch on August 17, 2026. This planned sale is related to the cashless exercise of employee stock options. The filing also reveals multiple prior significant sales by Rodman over the past three months, including transactions totaling over six figures in June, July, and August 2026.
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE
Bank of America Corp DE increased its stake in Mineralys Therapeutics (MLYS) by 11.5% in the first quarter, now owning 1.10 million shares valued at approximately $29.8 million. The company reported a significant second-quarter loss of $2.85 per share, substantially missing the expected $0.55 loss. Investors are also monitoring the December 22, 2026, PDUFA target date for its hypertension treatment, lorundrostat.
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"
Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share against a consensus of $0.55, and analysts expecting a full-year loss of $3.89 per share. However, Mineralys retains potential catalysts including a regulatory decision for its investigational hypertension treatment, lorundrostat, in December 2026, and sufficient funding into 2028.
Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen
Wall Street Zen downgraded Mineralys Therapeutics (NASDAQ:MLYS) to "Strong Sell" following a significant second-quarter earnings miss, where the company lost $2.85 per share against an expected $0.55 loss. Despite this, the broader analyst consensus remains a "Moderate Buy" with a $49.33 price target. Insider selling has also been noted, with executives selling approximately $5.6 million in stock over the past 90 days, while institutional investors hold 84.46% of the company.
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares
Mineralys Therapeutics insider David Rodman has filed a Form 144, indicating his intention to sell up to 14,056 shares of common stock through Merrill Lynch on or after August 13, 2026. The aggregate market value of the planned sale is $372,187.00. These shares originate from exercised employee stock options, including 7,707 shares via a cashless exercise and 6,349 shares for cash.
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced an inducement stock option award of 135,000 shares and a restricted stock unit award of 102,400 shares to Dr. Terry Ferguson, their new Chief Medical Officer. These awards, granted on August 10, 2026, are part of the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period, subject to continued service. The grants comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement for Dr. Ferguson's employment.
Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards
Mineralys Therapeutics (Nasdaq: MLYS) announced that its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson on August 10, 2026. These awards include a stock option for 135,000 shares and a restricted stock unit (RSU) award for 102,400 shares, both vesting over four years subject to continued service. The grants were made under the company's 2025 Employment Inducement Incentive Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced an inducement stock option award covering 135,000 shares and a restricted stock unit award covering 102,400 shares to Dr. Terry Ferguson, their new Chief Medical Officer. These awards, granted on August 10, 2026, are part of the company's 2025 Employment Inducement Incentive Award Plan and vest over a four-year period, subject to Dr. Ferguson's continued service. The awards were made as a material inducement for his employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics, Inc. announced an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of common stock to Dr. Terry Ferguson, its newly appointed Chief Medical Officer. These awards, granted on August 10, 2026, were made under the company's 2025 Employment Inducement Incentive Award Plan and are subject to vesting schedules. The inducement is material to Dr. Ferguson's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback
Mineralys Therapeutics (MLYS) reported a wider Q2 2026 net loss of US$241.07 million, alongside confirming a December 22, 2026 PDUFA date for lorundrostat and repurchasing a royalty obligation. This update highlights the company's focus on regulatory progress and enhancing the long-term economics of its lead asset, while also sharpening concerns about cash burn and future financing needs. The company's recent financing package supports pre-launch activities but underscores increased losses and interest obligations as investors weigh approval upside against financial risks.
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,170 stock options for common stock at $16.00 per share and subsequently sold those 2,170 shares at $27.09 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in October 2025. Following these transactions, Rodman directly holds 13,024 stock options and 51,384 common shares.
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock
Mineralys Therapeutics insider David Malcom Rodman sold 2,170 shares of the company's stock for $58,785.30, reducing his holdings by 4.05%. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, follows several other sales by Rodman in recent months. The company recently reported a significant second-quarter loss of $2.85 per share, missing analyst expectations, but maintains a "Moderate Buy" consensus rating from analysts with an average price target of $49.33, with a PDUFA target date for lorundrostat set for December 22, 2026.
